Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

x of Severity (CDEIS) was observed in the 500 mg QD group compared to placebo (CDEIS decrease of -8.4 vs. -1.1 for placebo, p=0.049). C-reactive protein (CRP) results confirmed the effect of 500 mg QD Traficet-EN. Traficet-EN may offer a new orally available treatment option with a favorable side effect profile to patients with this chronic gastrointestinal disease.

"Targeting the CCR9 chemokine receptor represents a new and highly specific approach to treating patients with Crohn's disease and potentially ulcerative colitis," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "No cure exists for inflammatory bowel diseases and many patients do not respond to or cannot tolerate current treatment options, including the newer biologics such as anti-Tumor Necrosis Factor (TNF) agents, which need to be injected or infused. There was no evidence of an increased risk of infection with Traficet-EN in PROTECT-1. This safety and efficacy profile may translate into a meaningful treatment option for patients."

"These data highlight a year of unparalleled clinical development progress by the ChemoCentryx team. This is true not only for our CCR9 program, but throughout our entire pipeline," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Traficet-EN results announced today underscore our leadership position in CCR9-based therapeutics for the treatment of inflammatory bowel diseases."

The randomized, placebo-controlled, double-blind PROTECT-1 clinical trial of more than 430 patients is comprised of three discrete phases which allows for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. The Induction Phase of the study is followed by a four-week, open label 'Active Period', during which all subje
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Four studies highlighting late-breaking research advances in the treatment ... at the 50th Annual Meeting of the American Society of ... Results from a study examining the ability of ... the inner lining of blood vessels, in patients with sickle ...
... at ASH Annual Meeting- , , ... announced results of a randomized phase III study presented ... of Hematology. The study in adult patients with hematological ... syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma ...
Cached Medicine Technology:Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 2Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 3Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 4Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 5Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 6Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 7Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 8Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 9Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/14/2014)... City, NJ (PRWEB) July 14, 2014 ... the established global leader in enterprise-class cloud management, ... collaboration platforms, today announced AvePoint software will be ... leading managed cloud specialist. , The ... Rackspace to offer the following AvePoint solutions to ...
(Date:7/14/2014)... 2014 Many diet plans often recommend eating ... the School of Public Health at the University of Alabama ... near-zero effect on weight loss. Now experts are suggesting that ... form of portion control to trigger measurable weight ... and controlling how much is consumed, simply by using a ...
(Date:7/14/2014)... Kenn Renner recently released a new video describing his ... the business on Austin Real Estate Investments . , ... Renner – is internationally recognized for his combined expertise on ... Investing in real estate is a great way for people ... career, while others like to do it as a hobby. ...
(Date:7/14/2014)... Seattle, WA (PRWEB) July 14, 2014 ... eat,' but what exactly does that mean?” This question ... and recently featured on Western Washington Medical Group’s blog ... with their mental health in mind . , According ... caffeinated beverages are placing themselves at a high risk ...
(Date:7/14/2014)... Milpitas, CA, and Washington DC (July 14, 2014) ... will be at Microsoft Worldwide Partner Conference 2014 (WPC) ... to showcase its award-winning information archiving and eDiscovery platforms ... 365, Windows servers, SharePoint, and Azure cloud network in ... “In the information archiving and legal discovery space for ...
Breaking Medicine News(10 mins):Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Drink With Your Mental Health in Mind, Advises an Article by Mental Health America Featured by Western Washington Medical Group 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5
... academics have been awarded funds from a huge European ... of individual people which could lead to everyone ... genetic and physiological make-up. Under the system, doctors ... of an individual patient,s health needs and medical history ...
... Steven Reinberg HealthDay Reporter , SUNDAY, July 24 ... new anti-clotting drug, Eliquis, to dual antiplatelet therapy may result ... and stroke, a new study finds. A trial evaluating ... severe bleeding among those taking Eliquis (apixaban) became apparent. ...
... July 23 (HealthDay News) -- Swimming may be easy on ... The most common injury among those who practice the ... percent of competitive swimmers, said Dr. Scott A. Rodeo, co-chief ... Special Surgery in New York City, who recently spoke at ...
... News) -- The ability of dolphins to resist infection and ... the treatment of human wounds, a researcher suggests. , ... documented," Dr. Michael Zasloff, adjunct professor at Georgetown University Medical ... news release. "How does the dolphin not bleed ...
... study by researchers at Drexel University,s School of Public Health ... gateway to the use of injected drugs such as heroin, ... drugs. The study, published in the International Journal of ... initiation into the misuse of opioid drugs. Common factors identified ...
... Amanda Gardner HealthDay Reporter , THURSDAY, July 21 ... Internet on their smartphones tend to hold the devices closer ... to work harder than usual, new research shows. This ... smartphones -- could put added strain on people who already ...
Cached Medicine News:Health News:Computer program could 'revolutionize the world's health care' 2Health News:Computer program could 'revolutionize the world's health care' 3Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 3Health News:Common Swimming Injuries Often Avoidable 2Health News:Dolphins' Superior Ability to Heal May Help Humans 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 3Health News:Smartphones May Be Taxing Your Eyes 2Health News:Smartphones May Be Taxing Your Eyes 3
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - Ready-to-Use Sterile, Enclosed System...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
... The Model 700 Whole Blood/Optical Lumi-Aggregometer available ... This new Aggregometer measures platelet function on ... blood or optical density in plasma with ... method. The Model 700 Aggregometer also has ...
Medicine Products: